Document is current

Documents that mention this clinical trial

589 BASECAMP-1 is an efficient pre-screening study that identifies patients with HLA LOH and provides mutational, RNA-Seq, and microbiome data for precision logic-gated CAR T therapeutic trials
https://doi.org/10.1136/jitc-2024-sitc2024.0589

634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)
https://doi.org/10.1136/jitc-2023-sitc2023.0634

BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials
https://doi.org/10.1136/bmjonc-2025-001033

77 An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity
https://doi.org/10.1136/jitc-2022-sitc2022.0077

229 A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer
https://doi.org/10.1136/jitc-2022-sitc2022.0229

636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials
https://doi.org/10.1136/jitc-2023-sitc2023.0636

Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability.
https://doi.org/10.1200/jco.2023.41.4_suppl.209

588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH
https://doi.org/10.1136/jitc-2024-sitc2024.0588

Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).
https://doi.org/10.1200/jco.2024.42.16_suppl.1604

491 BASECAMP-1: an observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy
https://doi.org/10.1136/jitc-2021-sitc2021.491

535 EVEREST-2: a phase 1/2 study of A2B694, a logic-gated Tmod CAR T therapy to treat solid tumors expressing mesothelin (MSLN) with HLA-A*02 loss of heterozygosity: initial safety and efficacy results
https://doi.org/10.1136/jitc-2025-sitc2025.0535

585 DENALI-1: a seamless phase 1/2 study of A2B395, a logic-gated, allogeneic, Tmod CAR T therapy, in patients with EGFR-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
https://doi.org/10.1136/jitc-2025-sitc2025.0585

639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy
https://doi.org/10.1136/jitc-2022-sitc2022.0639

627 EVEREST-2: a seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
https://doi.org/10.1136/jitc-2024-sitc2024.0627

263 A2B694, an autologous logic-gated cell therapy targeting mesothelin
https://doi.org/10.1136/jitc-2022-sitc2022.0263